Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer

PURPOSE: Neuroendocrine prostate cancer (NEPC) is an aggressive form of castration-resistant prostate cancer (CRPC) for which effective therapies are lacking. We previously identified carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) as a promising NEPC cell surface antigen. Here w...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: DeLucia, Diana C., Cardillo, Thomas M., Ang, Lisa, Labrecque, Mark P., Zhang, Ailin, Hopkins, James E., De Sarkar, Navonil, Coleman, Ilsa, da Costa, Rui M. Gil, Corey, Eva, True, Lawrence D., Haffner, Michael C., Schweizer, Michael T., Morrissey, Colm, Nelson, Peter S., Lee, John K.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7854497/
https://ncbi.nlm.nih.gov/pubmed/33199493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3396
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires